GlassScriptPhysician profile
Donald D Harper
NPI 1013170919
$2,503.43
in general payments reported to CMS, 2019-2025
21 companies · $737 in 2025
The $737 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $365 · 2023: $307 · 2024: $842 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.33 | 2022-2025 | |
| Novo Nordisk INC | $313.03 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $293.74 | 2021-2025 | Mounjaro, Zepbound |
| Corium, LLC | $245.22 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $199.56 | 2021-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $191.13 | 2025 | Jornay Pm |
| Pfizer INC. | $146.34 | 2021-2025 | |
| Axsome Therapeutics, INC. | $141.42 | 2025 | Auvelity, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $100.98 | 2024-2025 | |
| Exact Sciences Corporation | $100.33 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.90 | 2021-2022 | |
| Organon LLC | $63.37 | 2024-2025 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $57.97 | 2021-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $40.98 | 2022 | |
| Glaxosmithkline, LLC. | $36.80 | 2022-2023 | Trelegy Ellipta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.78 | 2021 | |
| Boston Scientific Corporation | $20.18 | 2021 | |
| Dexcom, INC. | $17.21 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $16.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.11 | 2022 | |
| Amgen INC. | $14.70 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.